Breast cancer is a molecularly heterogeneous disease and the most common female malignancy. In recent years

therapy approaches have evolved to accommodate molecular diversity

with a focus on more biologically based therapies to minimize negative consequences. To regulate cell fate in human breast cells

the Hippo signaling pathway has been associated with the alpha subtype of estrogen receptors. This pathway regulates tissue size

regeneration

and healing

as well as the survival of tissue-specific stem cells

proliferation

and apoptosis in a variety of organs

allowing for cell differentiation. Hippo signaling is mediated by the kinases MST1

MST2

LATS1

and LATS2

as well as the adaptor proteins SAV1 and MOB. These kinases phosphorylate the downstream effectors of the Hippo pathway

yes-associated protein (YAP)

and transcriptional coactivator with PDZ-binding motif (TAZ)

suppressing the expression of their downstream target genes. The Hippo signaling pathway kinase cascade plays a significant role in all cancers. Understanding the principles of this kinase cascade would prevent the occurrence of breast cancer. In recent years

small noncoding RNAs

or microRNAs

have been implicated in the development of several malignancies

including breast cancer. The interconnections between miRNAs and Hippo signaling pathway core proteins in the breast

on the other hand

remain poorly understood. In this review

we focused on highlighting the Hippo signaling system

its key parts

its importance in breast cancer

and its regulation by miRNAs and other related pathways.